Despite unconvincing results so far with next-gen IL-2 agents, plenty of groups are still crowding into this space.
The depressed company’s bempegaldesleukin, which underwhelmed in melanoma, now faces two key near-term clinical data readouts.
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
Alkermes plays up responses in mucosal melanoma, but those hoping for an IL-2 renaissance might be disappointed.
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.